跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
閻 雲
講座教授
,
癌症生物學與藥物研發研究所
成員
,
臺北醫學大學細胞治療與再生醫學研究中心
https://orcid.org/0000-0003-0815-412X
電子郵件
yyen
tmu.edu
tw
h-index
19095
引文
67
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1994 …
2025
每年研究成果
概覽
指紋
網路
專案
(47)
研究成果
(362)
資料集
(7)
類似的個人檔案
(6)
指紋
查看啟用 Yun Yen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
86%
Ribonucleotide Reductase
74%
Neoplasm
50%
Gemcitabine
28%
Breast Cancer
28%
Liver Cell Carcinoma
25%
Pharmacokinetics
25%
Biological Marker
22%
Disease
22%
Solid Malignant Neoplasm
21%
Hydroxycarbamide
20%
Nanoparticle
18%
Phase I Trials
16%
Mouse
16%
Overall Survival
16%
Camptothecin
15%
Tumor Growth
15%
Chemotherapy
15%
Small Interfering RNA
15%
Maximum Tolerated Dose
13%
Fibroblast Growth Factor Receptor 3
13%
Protein P53
12%
Clinical Trial
12%
Carcinogenesis
12%
Non Small Cell Lung Cancer
11%
Doxorubicin
11%
Bile Duct Carcinoma
10%
3 Aminopicolinaldehyde Thiosemicarbazone
10%
Cisplatin
10%
microRNA
10%
Multiple Myeloma
10%
Progression Free Survival
10%
Carboplatin
9%
Pancreas Cancer
9%
High Dose Chemotherapy
9%
Pharmacodynamics
9%
Anticarcinogen
9%
Drug Resistance
9%
Phase II Trials
9%
Colorectal Cancer
8%
Vasculotropin
8%
Bortezomib
7%
Oxaliplatin
7%
Histone Deacetylase Inhibitor
7%
Prostate Cancer
7%
Cyclodextrin
7%
Antitumor Activity
7%
Colon Cancer
6%
Holoenzyme
6%
Western Blot
6%
Biochemistry, Genetics and Molecular Biology
Ribonucleotide Reductase
100%
Cancer Cell
63%
Messenger RNA
23%
P53
23%
RRM2
19%
DNA Repair
17%
Hydroxycarbamide
16%
Gemcitabine
16%
Small Interfering RNA
16%
Carcinogenesis
14%
High-Mobility Group
13%
RRM2B
13%
Gene Expression
12%
Cell Proliferation
12%
Mouse
12%
Autophagy
12%
Drug Resistance
12%
Enzyme
12%
MicroRNA
12%
Oxidative Stress
11%
Promoter Region
11%
DNA Damage
11%
DNA Replication
11%
Cytotoxicity
10%
Wild Type
10%
Stem Cell
9%
Histone Deacetylase
9%
RNA
8%
Homeostasis
8%
Phosphotransferase
8%
Kinase
8%
Colon
8%
Overall Survival
8%
DNA Synthesis
8%
DNA Damage Checkpoint
8%
Arginine
7%
Cell Survival
7%
Cell Cycle
7%
Metabolite
7%
DNA Damage Response
6%
Signal Transduction
6%
Enzyme Activity
6%
Clinical Trial
6%
Ribonucleotide Reductase Inhibitor
6%
Tumor Progression
6%
Mitochondrion
6%
Tumor Suppressor Protein
6%
Cell Growth
6%
Microarrays
6%
Small Molecule
6%
Medicine and Dentistry
Malignant Neoplasm
38%
Breast Cancer
31%
Neoplasm
30%
Ribonucleotide Reductase
23%
Cancer Cell
22%
Hepatocellular Carcinoma
21%
Biological Marker
18%
Cholangiocarcinoma
17%
Disease
15%
Carcinogenesis
13%
Arginine
13%
Cancer
13%
Signal Transduction
13%
Metastatic Carcinoma
12%
Overall Survival
11%
microRNA
10%
In Vitro
10%
Non Small Cell Lung Cancer
10%
Clinical Trial
9%
Programmed Cell Death
9%
Stem Cell
9%
High Dose Chemotherapy
8%
Radiation Therapy
8%
Immunohistochemistry
8%
Hepatobiliary Cancer
7%
Fibroblast Growth Factor Receptor 3
7%
Gemcitabine
7%
Autophagy
7%
Recurrent Disease
7%
Histone Deacetylase Inhibitor
7%
Colorectal Cancer
7%
Antineoplastic Activity
6%
Drug Therapy
6%
Cisplatin
6%
Prostate Cancer
6%
Tumor Progression
6%
Triple Negative Breast Cancer
6%
Protein P53
6%
Gene Expression
5%
Oral Implants
5%
Pancreas Cancer
5%
Epidermal Growth Factor Receptor
5%
Adenocarcinoma
5%
Tumor Cell
5%
Progression Free Survival
5%
Diagnosis
5%
Cell Line
5%
Targeted Therapy
5%
Vasculotropin
5%
Stomach Cancer
5%
